Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
What to expect on compounded GLP-1 therapy Most patients start at 25 units (1.5 mg) of tirzepatide twice weekly or 25 units (0.15 mg) of semaglutide twice weekly
Bill both codes on the same claim
doi: 10.1016/j.ecoenv.2021.112115 202 FengYHZhangXPLiWXGuoXD
Very convenient and nice to have at home when needed
